Fig. 8: Targeting DMBT1 to treat liver metastasis.

a–d In vitro analysis of the DMBT1 neutralizing antibody clone 3H11. Shown are DMBT1–MUC1 interaction in KCs after 3H11 treatment (a), CD62L⁺ polarization (b), Ccl8 expression of KCs treated with DMBT1-containing tumoral CM with or without treatment of 3H11 (c) and NETosis of neutrophils after treatment of CM of the above KCs (d). e–i 3H11 treatment (100 μg/mouse) of C57BL/6 mice after intrasplenic inoculation of Py8119 cells. Shown are CD62L⁺ KC abundance (e), NETosis (f, zoomed areas shown at bottom) in livers, in vivo BLI (g), ex vivo BLI of livers and representative images of metastases (h), and body weight changes of the mice (i). j Schematic model of the tumor–KC–neutrophil interaction in breast cancer liver metastasis (figure created with elements from Biorender.com). n = 3 biological repeats (b–d) or 6 mice (e–i). P values were obtained by repeated measures two-way ANOVA (g) or two-tailed unpaired t-test (others). Scale bars, 50 μm. Data are shown as mean ± SEM (g) or mean ± SD (others).